As a compound having a potent oral activity and along-lasting cysLT1/cysLT2 receptor antagonistic activity,the compound of the formula (I):(see formula I)which exhibits potent antagonistic activity against thecysLT1/cysLT2 receptor, and have long-lasting effects evenin case of oral administration, and therefore is usefulas an oral agent for preventing and/or treating a varietyof diseases, for example, respiratory disease (forexample, asthma (bronchial asthma, etc.), chronicobstructive pulmonary disease (COPD), pulmonaryemphysema, chronic bronchitis, pneumonia (interstitialpneumonia, etc.), severe acute respiratory syndrome(SARS), acute respiratory distress syndrome (ARDS), apneasyndrome, allergic rhinitis, sinusitis (acute sinusitis,chronic sinusitis, etc.), pulmonary fibrosis, coughing(chronic coughing, etc.), and the like) was developed.
